SEC Form 4 · accession 0001193125-26-264004
Dyne Therapeutics, Inc. · DYN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian S Posner
Director
Period of report
Jun 5, 2026
Accepted (ET)
Jun 9, 2026 · 5:06 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001818794
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 8, 2026 | P | 2,000 | $16.94 | A | 24,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $17.04 | Jun 5, 2026 | A | 35,152 | A | — | Jun 4, 2036 | Common Stock | 35,152 | 35,152 | D |
Explanation of responses
- F1This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.